drugset / Trial / NCT02148861
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneously administered NNC0148-0287 (insulin 287) in subjects with type 2 diabetes
Timeline
- Start
- 2014-05-26
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin icodec | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |